A new frontier in cancer treatment is opening up in Hyderabad, where a biotech startup is harnessing the power of mRNA technology to create vaccines tailored to a patient's own tumour. This could be a turning point in personalised medicine.
The Dawn of Personalised Cancer Care
Imagine a cancer
treatment that isn't a one-size-fits-all solution, but a highly specific weapon designed exclusively for your body. This is the promise of personalised cancer vaccines, a revolutionary approach that is now taking root in India. Hyderabad-based startup PopVax has launched a new facility, the RNA Foundry, dedicated to developing and manufacturing these bespoke treatments. Unlike traditional vaccines that prevent infectious diseases, these are therapeutic vaccines designed to treat existing cancer. The core idea is to train a patient's own immune system to identify and destroy cancer cells with precision, using the unique genetic signature of their tumour as a guide.
How the 'Self' Vaccine Works
The process begins with the patient. Scientists take a sample of a person's tumour and sequence its genetic material to find mutations that are unique to the cancer cells and not present in healthy cells. These mutations often create abnormal proteins called neoantigens, which can act as 'wanted posters' for the immune system. This is where PopVax's cutting-edge technology comes in. Using artificial intelligence and machine learning, the company sifts through the genetic data to identify the most promising neoantigens that can trigger a strong immune response. An mRNA (messenger RNA) vaccine is then designed and manufactured to carry instructions for these specific neoantigens. When the vaccine is administered, it tells the body's cells to produce these harmless tumour proteins, effectively teaching the immune system what to look for and attack.
The RNA Foundry: A Hub for Innovation
The launch of the RNA Foundry on October 30, 2026, marks a significant step. It's an integrated research, development, and manufacturing facility built in collaboration with Stochastic Sciences. This isn't a typical large-scale vaccine plant; it's a specialised facility capable of producing a unique vaccine for each patient. PopVax aims to produce over 100 patient-specific vaccines within the next year. The startup, founded in 2021 by Soham Sankaran, has rapidly grown, leveraging its platform for other diseases and securing funding from prominent sources like the Gates Foundation and Good Ventures. While the company has a COVID-19 vaccine candidate in clinical trials, the cancer vaccine program is still in its early stages and will require its own trials to prove safety and efficacy.
Hyderabad's Rise as a Global Biotech Powerhouse
PopVax's ambitious project is not happening in a vacuum. It is deeply embedded in Hyderabad's flourishing life sciences ecosystem. The city, often called the 'Vaccine Hub of India', contributes to a third of the world's vaccine production. Its Genome Valley is India's premier biotech cluster, hosting over 200 companies, including major global and domestic players. The Telangana government has been actively fostering this environment with policies aimed at attracting investment and building world-class infrastructure, solidifying the city's reputation as a destination for advanced medical research in areas like gene therapies and biologics. PopVax's RNA Foundry adds a crucial private-sector capability for advanced mRNA manufacturing to this ecosystem, reinforcing Hyderabad's position on the global biotech map.
